Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment

American Journal of Obstetrics and Gynecology

Volumn 215, Issue 2, 2016, Pages 212.e1-212.e15

  Hildesheim, Allan ^a,e   Gonzalez, Paula ^b   Kreimer, Aimée R ^e   Wacholder, Sholom ^a,e   Schussler, John ^c   Rodriguez, Ana C ^b   Porras, Carolina ^b,e   Schiffman, Mark ^a,e   Sidawy, Mary ^d,e   Schiller, John T ^a,e   Lowy, Douglas R ^a,e   Herrero, Roland ^e   Cortés, Bernal ^e   González, Paula ^e   Jiménez, Silvia E ^e   Rodríguez, Ana Cecilia ^e   Sherman, Mark ^e   Pinto, Ligia ^e   Kemp, Troy ^e   Quint, Wim ^e   van Doorn, Leen Jan ^e   Palefsky, Joel M ^e   Darragh, Teresa M ^e   Stoler, Mark H ^e   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b Proyecto Epidemiológico Guanacaste   (Brazil)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e NONE

Author keywords

cervical cancer; clinical trial; human papillomaviruses; prevention; vaccines

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ELECTROSURGERY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; INCIDENCE; INFECTION RATE; NORMAL HUMAN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRAL CLEARANCE; ADOLESCENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84962682226     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.02.021     Document Type: Article

References (17)

1. 1 Kjaer, S.K., Sigurdsson, K., Iversen, O.E., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2 (2009), 868–878.
2. 2 Lehtinen, M., Paavonen, J., Wheeler, C.M., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13 (2012), 89–99.
3. 3 Hildesheim, A., Wacholder, S., Catteau, G., et al. Efficacy of the HPV-16/18 Vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 Vaccine Trial. Vaccine 32 (2014), 5087–5097.
4. 4 Schiller, J.T., Lowy, D.R., Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 10 (2012), 681–692.
5. 5 De Bruijn, M.L.H., Greenstone, H.L., Vermeulen, H., et al. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250 (1998), 371–376.
6. 6 Hildesheim, A., Herrero, R., Wacholder, W., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 (2007), 743–753.
7. 7 Haupt, R.M., Wheeler, C.M., Brown, D.R., et al. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer 129 (2011), 2632–2642.
8. 8 Szarewski, A., Poppe, W.A.J., Skinner, S.R., et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 131 (2012), 106–116.
9. 9 Joura, E.A., Garland, S.M., Paavonen, J., et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ, 344, 2012, e1401.
10. 10 Kang, W.D., Choi, H.S., Kim, S.M., Is vaccination with quadrivalent HPV vaccine after LEEP effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?. Gynecol Oncol 130 (2013), 264–268.
11. 11 Swedish, K.A., Factor, S.H., Goldstone, S.E., Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 54 (2012), 891–898.
12. 12 Herrero, R., Herrero, R., Hildesheim, A., et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 26 (2006), 4795–4808.
13. 13 Nayar, R., Solomon, D., Second edition of ‘The Bethesda System for reporting cervical cytology’ – atlas, website, and Bethesda interobserver reproducibility project. Cytojournal, 1, 2004, 4.
14. 14 The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 92 (2000), 397–402.
15. 15 Kleter, B., van Doorn, L.J., Schrauwen, L., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37 (1999), 2508–2517.
16. 16 Kleter, B., van Doorn, L.J., ter Schegget, J., et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 153 (1998), 1731–1739.
17. 17 van Doorn, L.J., Molijn, A., Kleter, B., Quint, W., Colau, B., Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 44 (2006), 3292–3298.